X-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitors

References

• Soprano DR, Herbert J, Soprano KJ, et al. Demonstration of transthyretin mRNA in the brain and other extrahepatic tissues in the rat. J Biol Chem 1985;260:11793–8
   PubMed Web of Science ®Google Scholar
• Martone RL, Herbert J, Dwork A, Schon EA. Transthyretin is synthesized in the mammalian eye. Biochem Biophys Res Commun 1988;151:905–12
   PubMed Web of Science ®Google Scholar
• Landers KA, Mortimer RH, Richard K. Transthyretin and the human placenta. Placenta 2013;34:513–17
   PubMed Web of Science ®Google Scholar
• Chanoine JP, Alex S, Fang SL, et al. Role of transthyretin in the transport of thyroxine from the blood to the choroid plexus, the cerebrospinal fluid, and the brain. Endocrinology 1992;130:933–8
   PubMed Web of Science ®Google Scholar
• Wojtczak A, Cody V, Luft JR, Pangborn W. Structures of human transthyretin complexed with thyroxine at 2.0 Å resolution and 3′,5′-dinitro-Nacetyl-L-thyronine at 2.2 Å resolution. Acta Crystallogr D Biol Crystallogr 1996;52:758–65
   PubMed Web of Science ®Google Scholar
• Westermark P, Sletten K, Johansson B, Cornwell GG 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990;87:2843–5
   PubMed Web of Science ®Google Scholar
• Saraiva MJ. Transthyretin mutations in health and disease. Hum Mutat 1995;5:191–6
   PubMed Web of Science ®Google Scholar
• Buxbaum JN, Tagoe CE. The genetics of the amyloidoses. Annu Rev Med 2000;51:543–69
   PubMed Web of Science ®Google Scholar
• Hammarstrom P, Wiseman RL, Powers ET, Kelly JW. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713–16
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005;121:73–85
   PubMed Web of Science ®Google Scholar
• Pilato E, Dell’more A, Botta L, Arpesella G. Combined heart and liver transplantation for familial amyloidotic neuropathy. Eur J Cardio-Thoracic Surg 2007;32:180–2
   PubMed Web of Science ®Google Scholar
• Connelly S, Choi S, Johnson SM, et al. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol 2010;20:54–62
   PubMed Web of Science ®Google Scholar
• Saraiva MJ. Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies. Expert Rev Mol Med 2002;4:1–11
   PubMedGoogle Scholar
• Almeida MR, Gales L, Damas AM, et al. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disorders 2005;4:587–96
   PubMedGoogle Scholar
• Ong DS, Kelly JW. Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases. Curr Opin Cell Biol 2011;23:231–8
   PubMed Web of Science ®Google Scholar
• Blake CC GM, Oatley SJ, Rerat B, Rerat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 Å. J Mol Biol 1978;121:339–56
   PubMed Web of Science ®Google Scholar
• Wojtczak A. Crystal structure of rat transthyretin at 2.5 A resolution: first report on a unique tetrameric structure. Acta Biochim Pol 1997;44:505–17
   PubMed Web of Science ®Google Scholar
• Andrea TA, Cavalieri RR, Goldfine ID, Jorgensen EC. Binding of thyroid hormones and analogues to the human plasma protein prealbumin. Biochemistry 1980;19:55–63
   PubMed Web of Science ®Google Scholar
• Foss TR, Wiseman RL, Kelly JW. The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 2005;44:15525–33
   PubMed Web of Science ®Google Scholar
• Nencetti S, Orlandini E. TTR fibril formation inhibitors: is there a SAR? Curr Med Chem 2012;19:2356–79
   PubMed Web of Science ®Google Scholar
• Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Investig 2004;84:545–52
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006;13:236–49
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013;310:2658–67
   PubMed Web of Science ®Google Scholar
• Palaninathan KS. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses? Curr Med Chem 2012;19:2324–42
   PubMed Web of Science ®Google Scholar
• Ciccone L, Tepshi L, Nencetti S, Stura EA. Transthyretin complexes with curcumin and bromo-estradiol: evaluation of solubilizing multicomponent mixtures. N Biotechnol 2015;32:54–64
   PubMed Web of Science ®Google Scholar
• Klabunde T, Petrassi HM, Oza VB, et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct Biol 2000;7:312–21
   PubMedGoogle Scholar
• Palaninathan SK, Mohamedmohaideen NN, Orlandini E, et al. Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis. PLoS One 2009;4:e6290
   Google Scholar
• Stura EA, Nemerow GR, Wilson IA. Strategies in the crystallization of glycoproteins and protein complexes. J Crystal Growth 1992;122:273–85
   Web of Science ®Google Scholar
• Vera L, Stura EA. Strategies for protein cryocrystallography. Crystal Growth Design 2014;14:427–35
   Web of Science ®Google Scholar
• Newman J. Novel buffer systems for macromolecular crystallization. Acta Crystallogr D Biol Crystallogr 2004;60:610–12
   PubMed Web of Science ®Google Scholar
• Diederichs K, Karplus PA. Better models by discarding data? Acta Crystallogr D Biol Crystallogr 2013;69:1215–22
   PubMed Web of Science ®Google Scholar
• Adams PD, Afonine PV, Bunkoczi G, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr Sect D. 2010;66:213–21
   PubMed Web of Science ®Google Scholar
• Pan HL, Fletcher TL. Derivatives of fluorenone XXX. Rearrangement and antitumor activities of some 9-oxofluorene oximes. 6(5H)-phenanthridones. J Med Chem 1969;12:822–5
   PubMed Web of Science ®Google Scholar
• Anet FAL, Bavin PMG, Dewar MJS. The reaction of nitromethane with fluorenone and benzophenone in polyphosphoric acid. Can J Chem 1957;35:180–2
   Web of Science ®Google Scholar
• Richardson A Jr. Aminooxyacetic acid derivatives. J Med Chem 1964;7:824–6
   PubMed Web of Science ®Google Scholar
• Stura EA. Strategy 3: reverse screening. In: Bergfors TE, ed. Crystallization of proteins: techniques, strategies and tips. A laboratory manual. La Jolla (CA): International University Line. 1999:113–24
   Google Scholar
• Stura EA, Wilson IA. Applications of the streak seeding technique in protein crystallization. J Cryst Growth 1991;110:270–82
   Web of Science ®Google Scholar
• Ciccone L, Vera L, Tepshi L, et al. Multicomponent mixtures for cryoprotection and ligand solubilization. Biotechnol Rep 2015;7:120–7
   Google Scholar
• Beteva A, Cipriani F, Cusack S, et al. High-throughput sample handling and data collection at synchrotrons: embedding the ESRF into the high-throughput gene-to-structure pipeline. Acta Crystallogr D Biol Crystallogr 2006;62:1162–9
   PubMed Web of Science ®Google Scholar
• Kabsch W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr D Biol Crystallogr 2010;66:133–44
   PubMed Web of Science ®Google Scholar
• Murshudov GN, Skubak P, Lebedev AA, et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 2011;67:355–67
   PubMed Web of Science ®Google Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010;66:486–501
   PubMed Web of Science ®Google Scholar
• Winn MD, Ballard CC, Cowtan KD, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 2011;67:235–42
   PubMed Web of Science ®Google Scholar
• Kleywegt GJ, Harris MR, Zou JY, et al. The Uppsala electron-density server. Acta Crystallogr D Biol Crystallogr 2004;60:2240–9
   PubMed Web of Science ®Google Scholar
• Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 2004;60:2256–68
   PubMed Web of Science ®Google Scholar
• Moses AC, Rosen HN, Moller DE, et al. A point mutation in transthyretin increases affinity for thyroxine and produces euthyroid hyperthyroxinemia. J Clin Investig 1990;86:2025–33
   PubMed Web of Science ®Google Scholar
• Green NS, Palaninathan SK, Sacchettini JC, Kelly JW. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J Am Chem Soc 2003;125:13404–14
   PubMed Web of Science ®Google Scholar
• Trivella DB, Bleicher L, Palmieri LC, et al. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding. J Struct Biol 2010;170:522–31
   PubMed Web of Science ®Google Scholar
• Lima LMTR, Silva VDA, Palmieri LDC, et al. Identification of a novel ligand binding motif in the transthyretin channel. Bioorg Med Chem 2010;18:100–10
   PubMed Web of Science ®Google Scholar